CN118019727A - 用于制备nlrp3抑制剂的方法 - Google Patents

用于制备nlrp3抑制剂的方法 Download PDF

Info

Publication number
CN118019727A
CN118019727A CN202280045202.0A CN202280045202A CN118019727A CN 118019727 A CN118019727 A CN 118019727A CN 202280045202 A CN202280045202 A CN 202280045202A CN 118019727 A CN118019727 A CN 118019727A
Authority
CN
China
Prior art keywords
group
typically
piperidine
solvent
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045202.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·弗雷泽
J·帕尔古纳
M·巴拉塔
J·E·F·辛奎布雷
R·J·G·蒙迪雷
P·托萨蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN118019727A publication Critical patent/CN118019727A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280045202.0A 2021-06-23 2022-06-23 用于制备nlrp3抑制剂的方法 Pending CN118019727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23
PCT/EP2022/067126 WO2022268935A2 (en) 2021-06-23 2022-06-23 Novel process

Publications (1)

Publication Number Publication Date
CN118019727A true CN118019727A (zh) 2024-05-10

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045202.0A Pending CN118019727A (zh) 2021-06-23 2022-06-23 用于制备nlrp3抑制剂的方法

Country Status (12)

Country Link
US (1) US20240150291A1 (https=)
EP (1) EP4359385A2 (https=)
JP (1) JP2024524215A (https=)
KR (1) KR20240024842A (https=)
CN (1) CN118019727A (https=)
AR (1) AR126215A1 (https=)
AU (1) AU2022300325A1 (https=)
CA (1) CA3219597A1 (https=)
IL (1) IL308071A (https=)
MX (1) MX2023014547A (https=)
TW (1) TW202317514A (https=)
WO (1) WO2022268935A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
IL325043A (en) 2023-08-16 2026-01-01 Hoffmann La Roche Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69727837T2 (de) * 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
JP5508027B2 (ja) * 2007-02-22 2014-05-28 メルク セローノ ソシエテ アノニム キノキサリン化合物及びその使用
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2022268935A3 (en) 2023-02-02
IL308071A (en) 2023-12-01
TW202317514A (zh) 2023-05-01
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
AR126215A1 (es) 2023-09-27
KR20240024842A (ko) 2024-02-26
AU2022300325A8 (en) 2023-11-16
AU2022300325A1 (en) 2023-11-02
WO2022268935A2 (en) 2022-12-29
CA3219597A1 (en) 2022-12-29
JP2024524215A (ja) 2024-07-05
MX2023014547A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
CN118019727A (zh) 用于制备nlrp3抑制剂的方法
JP2025527298A (ja) 三環式化合物及びその医薬用途
WO2014059938A1 (zh) 一种利拉列汀重要中间体的制备方法
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
AU2017304952A1 (en) Isoquinolinone compound and use thereof in preparation of antiviral drugs
CN110139868B (zh) 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法
KR20190084299A (ko) 피롤로 6-원 헤테로방향족 고리 유도체의 제조 방법 및 그의 중간체
WO2016164838A1 (en) Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
EP4479381A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
CN120584100A (zh) 用于制备nlrp3抑制剂的方法
TW202543613A (zh) 作為glp-1r激動劑的新型化合物及其用途
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
JP2024532558A (ja) チエノ縮合環化合物及びその調製方法と使用
WO2017021904A1 (en) Daclatasvir free base and process for the preparation thereof
EP1720867B1 (en) Process for the preparation of ziprasidone
HK40112968A (zh) 用於制备1,2,3,5,6,7-六氢-s-二环戊二烯并苯衍生物的方法
WO2007062335A2 (en) New pleuromutilin derivative and its use
TWI915407B (zh) Apol1抑制劑及其使用方法
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
CN117263850A (zh) 一种雷芬那辛的合成方法
CN118239883A (zh) 一类赖氨酸特异性脱甲基酶1(lsd1)抑制剂的制备方法
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные
HK40012866B (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
HK40012866A (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105889

Country of ref document: HK